Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $66.29

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have earned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $66.29.

JANX has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research note on Thursday, May 9th. BTIG Research initiated coverage on Janux Therapeutics in a research note on Thursday, March 21st. They issued a “buy” rating and a $62.00 price objective on the stock. Jonestrading initiated coverage on Janux Therapeutics in a research note on Tuesday, April 16th. They issued a “buy” rating and a $70.00 price objective on the stock. Bank of America lifted their price objective on Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th. Finally, Scotiabank initiated coverage on Janux Therapeutics in a research note on Thursday, May 30th. They issued a “sector perform” rating and a $47.00 price objective on the stock.

Insider Buying and Selling

In related news, CFO Tighe Reardon sold 822,721 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $45,043,974.75. Following the transaction, the chief financial officer now directly owns 633,673 shares of the company’s stock, valued at approximately $34,693,596.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Janux Therapeutics news, CFO Tighe Reardon sold 822,721 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $45,043,974.75. Following the transaction, the chief financial officer now directly owns 633,673 shares of the company’s stock, valued at approximately $34,693,596.75. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total value of $37,081,025.25. Following the completion of the transaction, the insider now directly owns 3,271,216 shares in the company, valued at $179,099,076. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,000,000 shares of company stock valued at $164,250,000. Corporate insiders own 35.40% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors have recently made changes to their positions in JANX. Lord Abbett & CO. LLC bought a new stake in shares of Janux Therapeutics in the 1st quarter valued at approximately $20,420,000. RA Capital Management L.P. increased its holdings in shares of Janux Therapeutics by 5.7% in the 3rd quarter. RA Capital Management L.P. now owns 9,165,652 shares of the company’s stock valued at $92,390,000 after acquiring an additional 495,008 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after acquiring an additional 378,477 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Janux Therapeutics by 27.8% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock valued at $11,592,000 after acquiring an additional 250,000 shares during the last quarter. Finally, Altitude Crest Partners Inc. bought a new stake in shares of Janux Therapeutics in the 1st quarter valued at approximately $7,278,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Price Performance

JANX opened at $41.72 on Friday. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -34.20 and a beta of 3.58. The business has a 50-day moving average of $47.65 and a two-hundred day moving average of $32.38. Janux Therapeutics has a 12 month low of $5.65 and a 12 month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. The company had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $0.98 million. Janux Therapeutics had a negative return on equity of 13.49% and a negative net margin of 762.92%. Equities research analysts anticipate that Janux Therapeutics will post -1.34 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.